Ocugen (NASDAQ:OCGN) Price Target Lowered to $7.00 at HC Wainwright

Ocugen (NASDAQ:OCGN - Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $8.00 to $7.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright also issued estimates for Ocugen's Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.22) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.17 EPS.

Separately, Chardan Capital restated a "buy" rating and set a $7.00 price target on shares of Ocugen in a research report on Monday, May 12th.

Ocugen Stock Performance

Shares of Ocugen stock traded up $0.05 during trading on Monday, hitting $0.76. 8,330,675 shares of the stock were exchanged, compared to its average volume of 4,446,748. The stock's fifty day moving average is $0.67 and its 200 day moving average is $0.76. The stock has a market cap of $221.47 million, a PE ratio of -4.21 and a beta of 4.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.58 and a current ratio of 2.58. Ocugen has a 12 month low of $0.52 and a 12 month high of $2.03.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01. The business had revenue of $1.48 million during the quarter. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. As a group, sell-side analysts anticipate that Ocugen will post -0.2 EPS for the current year.

Hedge Funds Weigh In On Ocugen

A number of institutional investors and hedge funds have recently bought and sold shares of OCGN. Renaissance Technologies LLC bought a new position in Ocugen in the 4th quarter valued at about $1,681,000. GMT Capital Corp grew its position in Ocugen by 69.2% in the 1st quarter. GMT Capital Corp now owns 4,153,798 shares of the company's stock valued at $2,934,000 after buying an additional 1,698,840 shares in the last quarter. Nuveen LLC bought a new position in Ocugen in the 1st quarter valued at about $535,000. GSA Capital Partners LLP grew its position in Ocugen by 43.0% in the 1st quarter. GSA Capital Partners LLP now owns 1,638,033 shares of the company's stock valued at $1,157,000 after buying an additional 492,300 shares in the last quarter. Finally, Jane Street Group LLC grew its position in Ocugen by 258.8% in the 4th quarter. Jane Street Group LLC now owns 496,177 shares of the company's stock valued at $399,000 after buying an additional 357,891 shares in the last quarter. Institutional investors own 10.27% of the company's stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.